294 related articles for article (PubMed ID: 31651200)
1. Clinical utility versus futility: a tipping point for liquid biopsies in bladder cancer.
Kouba E; Cheng L
Future Oncol; 2019 Nov; 15(33):3751-3753. PubMed ID: 31651200
[No Abstract] [Full Text] [Related]
2. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
3. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy in the clinical management of bladder cancer: current status and future developments.
Kouba E; Lopez-Beltran A; Montironi R; Massari F; Huang K; Santoni M; Chovanec M; Cheng M; Scarpelli M; Zhang J; Cimadamore A; Cheng L
Expert Rev Mol Diagn; 2020 Feb; 20(2):255-264. PubMed ID: 31608720
[No Abstract] [Full Text] [Related]
5. Liquid Biopsy in Bladder Cancer.
Cui Y; Cao M
Methods Mol Biol; 2023; 2695():111-120. PubMed ID: 37450114
[TBL] [Abstract][Full Text] [Related]
6. Recent progress with next-generation biomarkers in muscle-invasive bladder cancer.
Contreras-Sanz A; Roberts ME; Seiler R; Black PC
Int J Urol; 2017 Jan; 24(1):7-15. PubMed ID: 27597124
[TBL] [Abstract][Full Text] [Related]
7. The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA.
Rossi D; Kurtz DM; Roschewski M; Cavalli F; Zucca E; Wilson WH
Hematol Oncol; 2020 Feb; 38(1):34-37. PubMed ID: 31872890
[TBL] [Abstract][Full Text] [Related]
8. How liquid biopsies can change clinical practice in oncology.
Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
[TBL] [Abstract][Full Text] [Related]
9. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.
Giannopoulou L; Kasimir-Bauer S; Lianidou ES
Clin Chem Lab Med; 2018 Jan; 56(2):186-197. PubMed ID: 28753534
[TBL] [Abstract][Full Text] [Related]
11. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Vymetalkova V; Cervena K; Bartu L; Vodicka P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
[TBL] [Abstract][Full Text] [Related]
12. Liquid Biopsy and Lung Cancer.
Pisapia P; Malapelle U; Troncone G
Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
[TBL] [Abstract][Full Text] [Related]
13. Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction.
Yang Y; Miller CR; Lopez-Beltran A; Montironi R; Cheng M; Zhang S; Koch MO; Kaimakliotis HZ; Cheng L
Crit Rev Oncog; 2017; 22(5-6):389-401. PubMed ID: 29604919
[TBL] [Abstract][Full Text] [Related]
14. Role of liquid biopsies in colorectal cancer.
Wills B; Gorse E; Lee V
Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.
Liu SC
World J Gastroenterol; 2024 Apr; 30(15):2175-2178. PubMed ID: 38681986
[TBL] [Abstract][Full Text] [Related]
16. Potential of circulating biomarkers in liquid biopsy diagnostics.
Yeo JC; Lim CT
Biotechniques; 2018 Oct; 65(4):187-189. PubMed ID: 30284936
[No Abstract] [Full Text] [Related]
17. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
[TBL] [Abstract][Full Text] [Related]
18. Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Chamberlin MD; Wells JD; Shee K; Bean JR; Marotti JD; Wells WA; Trask HW; Kolling FW; Bhatt A; Kaufman PA; Schwartz GN; Gemery JM; McNulty NJ; Tsapakos MJ; Barth RJ; Arrick BA; Gui J; Miller TW
Breast Cancer Res Treat; 2020 Aug; 182(3):665-677. PubMed ID: 32562118
[TBL] [Abstract][Full Text] [Related]
19. Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities.
Beije N; Martens JWM; Sleijfer S
Drug Discov Today; 2019 Sep; 24(9):1715-1719. PubMed ID: 31170504
[TBL] [Abstract][Full Text] [Related]
20. Liquid Biopsy Technique May Allow Early Screening.
Cancer Discov; 2017 Nov; 7(11):1207. PubMed ID: 28903989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
